Program
aprocitentan
Also written as “Aprocitentan”, “Aprocitentan 25 mg” and “Aprocitentan tablets(SYH9108)”.
Its studies are mostly in Hypertension · Liver Diseases · Essential Hypertension · Renal Insufficiency, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Idorsia Pharmaceuticals | 130 open or running | phase 3since May 17, 2018 | Nov 9, 2015 | none ahead |
| CSPC Pharmaceutical Group | 11 open or running | phase 3since May 29, 2026 | May 29, 2026 | Dec 28, 2029phase 3 · NCT07635914 |
Also a collaborator on its studies: Johnson & Johnson.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 9, 2015First study: phase 2 study in Essential HypertensionNew to Idorsia PharmaceuticalsIdorsia Pharmaceuticals · NCT02603809 · 1,659 enrolled · United States, Canada, Israel and more
- Feb 24, 2016Phase 1 study in Healthy SubjectsIdorsia Pharmaceuticals · NCT02708004 · 24 enrolled · Switzerland
- Jul 20, 2016Phase 1 study in Healthy SubjectsIdorsia Pharmaceuticals · NCT02841761 · 20 enrolled · United States
- Mar 29, 2017Phase 1 study in Healthy SubjectsIdorsia Pharmaceuticals · NCT03100591 · 6 enrolled · Netherlands
- May 23, 2017Phase 1 study in Renal InsufficiencyIdorsia Pharmaceuticals · NCT03165071 · 16 enrolled · Czechia
- Aug 8, 2017Phase 1 study in Healthy SubjectsIdorsia Pharmaceuticals · NCT03245229 · 20 enrolled · Czechia
- May 17, 2018Phase 3 study in Resistant HypertensionIdorsia Pharmaceuticals · NCT03541174 · 730 enrolled · United States, Australia, Belgium and more
- Jul 2, 2018Phase 1 study in Healthy SubjectsIdorsia Pharmaceuticals · NCT03586570 · 20 enrolled · United States
- Nov 11, 2019Phase 3 study in HypertensionIdorsia Pharmaceuticals · NCT04162366
- Jan 31, 2020Phase 1 study in Liver DiseasesIdorsia Pharmaceuticals · NCT04252495 · 17 enrolled · Germany, Poland
- Feb 20, 2020Phase 1 study in Healthy SubjectsIdorsia Pharmaceuticals · NCT04281342 · 48 enrolled · Germany
- Jan 5, 2022Phase 1 study in Healthy SubjectsIdorsia Pharmaceuticals · NCT05196399 · 36 enrolled · Czechia
- Jan 14, 2025Phase 1 study in Drug Drug InteractionIdorsia Pharmaceuticals · NCT06799884 · 19 enrolled · Czechia
- May 29, 2026CSPC Pharmaceutical Group's first study: phase 3 study in Resistant HypertensionNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT07635914 · 382 planned
Ahead
- Dec 28, 2029Primary completion: phase 3 study in Resistant HypertensionCSPC Pharmaceutical Group · NCT07635914
TargetBeta
“Endothelin receptor, ET-A/ET-B antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Bosentanrule | Johnson & Johnson | phase 4 | 37 |
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07635914Resistant Hypertension | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Dec 28, 2029 | 382 |
| NCT06799884Drug Drug Interaction · Czechia | 1 | Completed | Idorsia Pharmaceuticals | Feb 21, 2025 | 19 |
| NCT05196399Healthy Subjects · Czechia | 1 | Completed | Idorsia Pharmaceuticals | Mar 27, 2022 | 36 |
| NCT04281342Healthy Subjects · Germany | 1 | Completed | Idorsia Pharmaceuticals | Aug 3, 2021 | 48 |
| NCT04252495Liver Diseases · Germany, Poland | 1 | Completed | Idorsia Pharmaceuticals | Apr 5, 2021 | 17 |
| NCT04162366Hypertension | 3 | Withdrawn | Idorsia Pharmaceuticals | Jun 30, 2021 | 0 |
| NCT03586570Healthy Subjects · United States | 1 | Completed | Idorsia Pharmaceuticals | Sep 10, 2018 | 20 |
| NCT03541174Resistant Hypertension · United States, Australia, Belgium and more | 3 | Completed | Idorsia Pharmaceuticals | May 14, 2021 | 730 |
| NCT03245229Healthy Subjects · Czechia | 1 | Completed | Idorsia Pharmaceuticals | Sep 18, 2017 | 20 |
| NCT03165071Renal Insufficiency · Czechia | 1 | Completed | Idorsia Pharmaceuticals | Oct 27, 2017 | 16 |
| NCT03100591Healthy Subjects · Netherlands | 1 | Completed | Idorsia Pharmaceuticals | Apr 18, 2017 | 6 |
| NCT02841761Healthy Subjects · United States | 1 | Completed | Idorsia Pharmaceuticals | Sep 1, 2016 | 20 |
| NCT02708004Healthy Subjects · Switzerland | 1 | Completed | Idorsia Pharmaceuticals | Dec 1, 2016 | 24 |
| NCT02603809Essential Hypertension · United States, Canada, Israel and more | 2 | Completed | Idorsia Pharmaceuticals | Feb 28, 2017 | 1,659 |
How it is read
Names in the registry
- “Aprocitentan”, 5 entries
- “Aprocitentan 25 mg”, 4 entries
- “Aprocitentan tablets(SYH9108)”, 1 entry
- “Aprocitentan 12.5 mg”, 1 entry
- “14C-radiolabeled ACT-132577”, 1 entry
Conditions, from the studies’ own filings
- Hypertension, 3 studies
- Liver Diseases, 1 study
- Essential Hypertension, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.